Downregulation of miR‐122 in the rodent and human hepatocellular carcinomas

By Huban Kutay, Shoumei Bai, J. Datta, Tasneem Motiwala, I. Pogribny, W. Frankel, S. Jacob, K. Ghoshal. Journal of Cellular Biochemistry, 2006

630 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/dc4da9c6617f438f58dbb558ecaf8ca4b2789eee

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties (2009, neutral): “Expression of miR-122 has been found to be repressed in HCC (Kutay et al., 2006; Murakami et al., 2006; Gramantieri et al., 2007; Braconi and Patel, 2008; Budhu et al., 2008; Girard et al., 2008; Ladeiro et al., Received 25 January 2009; revised 8 June 2009; accepted 18 June 2009; published online…”
Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. (2011, background): “MicroRNA-122 is the most abundant microRNA in the liver, and the repression of miR122 in HCC has been reported by many investigators.(7,26-29) Coulouarn et al(29) showed that the repression of miR-122 correlated with HBV-related HCC, tumor size, and differentiation grade.”
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. (2012, neutral): “miR-122 expression is reduced during the initiation and progression of hepatocarcinogenesis in a rat model of nonalcoholic steatohepatitis (NASH) (8), and downregulation of miR-122 is prevalent in human NASH patients (9).”
Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. (2011, background): “…et al., 2007, 2008, 2009; Braconi and Patel, 2008; Ji et al., 2009a, 2009b; Ladeiro et al., 2008; Varnholt et al., 2008; Wang et al., 2008, 2009a; Wong et al., 2008; Murakami et al., 2006; Kutay et al., 2006; Budhu et al., 2008; Ura et al., 2009; Coulouarn et al., 2009; Xiong et al., 2010).”
An overview of microRNAs (2015, background): “miRNAs are often reduced in cancer: for example, the liver-specific miR-122 in hepatocellular carcinoma[169, 170].”
MicroRNAs in development and disease. (2011, background): “This finding was observed in 50% of primary human tumors (324) as it appeared to correlate with poor prognosis, larger tumor size, c-Met positivity, and loss of the hepatocyte differentiation (123).”
MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death (2008, background): “…of translational repression of CCNG1, a p53 pathway antagonist CCNG1 and CAT-1ba Chang et al. (2004); Esau et al. (2006); Gramantieri et al. (2007); Kutay et al. (2006) R egulation by m iR N A s R S chickel et al 5 9 6 2 O n co g e n e O n co g e n e miRNAs in various human cancers clearly…”